Future strategies in the diagnosis, staging and treatment of bladder cancer

Current Opinion in Urology

Volumn 13, Issue 5, 2003, Pages 389-395

  Van Der Heijden, Antoine G ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Cystectomy; Diagnosis; Invasive bladder cancer; Prognostic markers; Staging; Superficial bladder cancer

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN C; PIRARUBICIN; PROTEIN P21; PROTEIN P27; PROTEIN P53; VALRUBICIN; VINBLASTINE;

BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; DNA MICROARRAY; DYSURIA; FLUORESCENCE; HEMATURIA; HUMAN; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

DIAGNOSTIC TECHNIQUES, UROLOGICAL; HUMANS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 0043263864     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200309000-00006     Document Type: Review

References (44)

1. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br J Urol 1994; 73:172-176.
2. Hoque MO, Lee CC, Cairns P, et al. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003; 63:2216-2222. In this article the single-nucleotide polymorphism analysis raises the possibility of individual tumour genome-wide allelotyping with potential prognostic and diagnostic applications.
3. Obermann EC, Junker K, Stoehr R, et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH Analyses. J Pathol 2003; 199:50-57. In this study flat hyperplasia detected by 5-ALA-induced fluorescence endoscopy was investigated. There was a good correlation between fluorescence in-situ hybridization, loss of heterozygosity, and comparative genomic hybridization analyses. Urothelial hyperplasias can display many genetic alterations commonly found in invasive bladder cancer, and could therefore be an early neoplastic lesion in the multistep development of invasive urothelial carcinoma.
4. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001; 54:215-221.
5. Sanchez-Carbayo M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin Chem 2003; 49:23-31. A review that shows that expression profiling with high-throughput DNA microarrays has the potential of providing critical clues for the management of bladder cancer patients.
6. Jichlinski P, Marti A, Leisinger HJ. Fluorescence cystoscopy in bladder cancer: what future? [in French]. Ann Urol (Paris) 2002; 36:264-268. A study showing that the application of fluorescence cystoscopy allows the detection of CIS with a sensitivity of 80-90%.
7. Zaak D, Hungerhuber E, Schneede P, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002; 95:1234-1238. The application of DNA technologies to provide novel biomarkers for bladder cancer are reviewed.
8. Duggan DJ, Bittner M, Chen Y, et al. Expression profiling using cDNA microarrays. Nat Genet 1999; 21 (1 Suppl.):10-14.
9. Sanchez-Carbaye, M. Use of high-throughput DNA microarrays to identify biomarkers for bladder cancer. Clin. Chem 2003; 49:23-31. In this orginal paper, expression profiles of bladder tumours have been analysed against a pool of bladder cancer cell lines by the use of cDNA micro-arrays.
10. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003; 33:90-96. This study identifies subclasses of bladder carcinoma using expression microarray analysis. Hierarchical cluster analysis identified three major stages, Ta, T1 and T2-4, with Ta tumours classified in subgroups.
11. Yiou R, Patard JJ, Benhard H, et al. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 2002; 89:374-378. This study suggests that the prognosis of superficial TCC, which progresses despite conservative management, is no better than that of invasive TCC at initial presentation, despite the closer follow-up of patients with a superficial tumour.
12. Santos LL, Amaro T, Pereira SA, et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29:74-80. In this immunohistochemical study the prognostic value of the expression of p16, p27, pRb, p53 and Ki-67 in superficial grade I and II papillary urothelial cell carcinoma of the bladder is studied. Ki-67 can be a reliable marker in predicting recurrence or progression in superficial low-grade TCC.
13. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000; 6:1854-1864.
14. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. P53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38:691-699.
15. Tiguert R, Lessard A, So A, Fradet Y. Prognostic markers in muscle invasive bladder cancer. World J Urol 2002; 20:190-195. This review provides an update on the most promising single markers and pathways, including the cell cycle markers p53, p21 and p27, and potential targets for novel therapies, such as cyclo-oxygenase 2 and angiogenesis factors.
16. Williams SG, Buscarini M, Stein JP. Molecular markers for diagnosis, staging, and prognosis of bladder cancer. Oncology (Huntington) 2001; 15:1461-1464, 1476.
17. Qureshi KN, Griffiths TR, Robinson MC, et al. Combined P21WAF1/CIP1 and p53 everexpressien predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radial Oncol Biol Phys 2001; 51:1234-1240.
18. Kausch I, Bohle A. Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol 2001; 39:498-506.
19. Hussain SA, Ganesan R, Hiller L, et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88:585-592. This study investigates the effect of the expression of a range of genes involved in apoptosis on outcome in bladder cancer. It was seen that the overexpression of BAX and CD40L are positive prognostic survival factors.
20. Newling DW, Hetherington J, Sundaram SK, et al. The use of valrubicin for the chemoresection of superficial bladder cancer - a marker lesion study. Eur Urol 2001; 39:643-647.
21. Okamura K, One Y, Kinukawa T, et al. Randomized study of single early instillation of (2″R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94:2363-2368. A prospective randomized study to determine whether a single tetrahydropyranyl instillation immediately after TUR is beneficial to patients with a single superficial bladder carcinoma. The results indicate that such an instillation immediately after TUR reduces the recurrence of superficial bladder carcinoma.
22. Cezzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacekinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999; 5:2629-2637.
23. Dalbagni G, Russe P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractery transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20:3193-3198. A phase I study to determine the safety and toxicity profile of gemcitabine administered intravesically in patients with TCC of the bladder. Gemcitabine has substantial activity as an intravesical agent. Therapy given twice weekly was associated with minimal bladder irritation and tolerable myelosuppression.
24. Paroni R, Salonia A, Lev A, et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001; 52:273-278.
25. Berger AP, Steiner H, Stenzl A, et al. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003; 61:338-341. A study to evaluate the efficacy and side-effects of PDT in patients with recurrent superficial bladder cancer. PDT represents a safe, effective, and less-invasive treatment for patients with recurrent superficial bladder cancer.
26. Nilsson S, Ragnhammar P, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 2001; 40:371-390.
27. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer, Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996; 156:1934-1940, discussion.
28. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970. A meta-analysis of published results of randomized clinical trials comparing TUR plus intravesical BCG with either resection alone or resection plus another treatment other than BCG. Intravesical BCG significantly reduces the risk of progression after TUR in patients with superficial bladder cancer who receive maintenance treatment.
29. Vallancien G, Abou El Fettouh, Cathelineau X, et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002; 168:2413-2417. In a study to minimize the risk of incontinence and impotence without compromising oncological outcome, prostate-sparing surgery during radical cystectomy for bladder cancer was performed. After one year follow-up 82% maintained potency and 97% were fully continent during the day.
30. Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 2002; 41:440-448. This study shows in a multivariate analysis that organ confinement and nodal status were the strongest independent predictors of disease-specific survival in all patient categories.
31. Frank I, Cheville JC, Blute ML, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003; 97:2425-2431. The goal of this study was to identify predictors of survival in a cohort with TCC metastatic to regional lymph nodes treated by cystectomy. Adjuvant chemotherapy and the number of positive lymph nodes were associated significantly with death from TCC.
32. Leissner J, Allhoff EP, Hohenfellner R, Wolf HK. Significance of pelvic lymphadenectomy for the prognosis after radical cystectomy [in German]. Zentralbl Chir 2002; 127:315-321. This study evaluates the correlation between the number of lymph nodes removed and the tumour-free survival in invasive bladder tumours. The more extensive lymphadenectomy significantly improves the prognosis of patients with invasive bladder cancer.
33. Herr HW, Bochner BH, Dalbagni G, et al. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298. At least nine lymph nodes should be studied to define the lymph node status accurately. These results indicate that lymphadenectomy is necessary in the proper staging of invasive bladder cancer.
34. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169:943-945. This paper shows that the number of lymph nodes examined and the quality of lymph node dissection was a significant prognostic variable for survival and local control in patients with lymph node-positive bladder cancer after radical cystectomy.
35. Levy DA, Grossman HB. Staging and prognosis of T3b bladder cancer. Semin Urol Oncol 1996; 14:56-61.
36. Shvarts O, Hart KR, Seltzer M, et al. Positron emission tomography in urologic oncology. Cancer Control 2002; 9:335-342. In this article the role of PET imaging in genitourinary malignancies is reviewed. The current role of PET in bladder cancer is still being defined.
37. Kosuda S, Kison PV, Greenough R, et al. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997; 24:615-620.
38. Raghavan D, Quinn D, Skinner DG, Stein JP. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol 2002; 11:55-63. This review analyses the results of published studies concerning treatment for invasive bladder cancer. Neoadjuvant chemotherapy trials show some benefit. However, adjuvant chemotherapy trials failed to show improved survival.
39. Segal R, Winquist E, Lukka H, et al. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Can J Urol 2002; 9:1625-1633. This paper contains guidelines for adjuvant chemotherapy in metastatic bladder cancer. Trials of gemcitabine-cisplatin and dose-intensive MVAC plus granulocyte colony-stimulating factor are reviewed. This provides indirect evidence that these regimens could offer equivalent benefit to MVAC and cisplatin-methotrexate-vinblastine, but with less toxicity in patients with muscle-invasive disease.
40. Culine S. The present and future of combination chemotherapy in bladder cancer. Semin Oncol 2002; 29 (3 Suppl. 9):32-39. Chemotherapeutic options, MVAC and gemcitabine-cisplatin are reviewed. Gemcitabine-cisplatin has similar efficacy and lower toxicity than the classic MVAC regimen.
41. Chahal R, Sundaram SK, Iddenden R, et al. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003; 43:245-257. This retrospective regional study shows that there is no significant difference in the 5-year survival of patients with invasive bladder cancer treated with either radical radiotherapy or radical cystectomy.
42. Mead GM, Russell M, Clark P, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council Study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998; 78:1067-7105.
43. von der Maase H, Hansen S, Roberts W, et al. Gemcitabine and cisplatin versus methotrexate, ninblastin, doxorubicin, and cisplatin in advanced or metastic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III Study. J. Clin Oncol 2000; 18:3068-7307.
44. Sternberg CN, Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classis MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 15 May 2001; 19:2638-2646.